- Home
- BMRN vs QXO Comparison
BMRN vs QXO Comparison
Compare BMRN & QXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMRN | QXO |
|---|---|---|
| Founded | 1996 | 1988 |
| Country | United States | United States |
| Employees | N/A | 7794 |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 11.8B |
| IPO Year | 1999 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BMRN | QXO |
|---|---|---|
| Price | $59.87 | $11.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 14 |
| Target Price | ★ $88.22 | $32.85 |
| AVG Volume (30 Days) | 1.7M | ★ 16.2M |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $1,313,646,000.00 | $54,516,941.00 |
| Revenue This Year | $15.02 | $70.27 |
| Revenue Next Year | $12.23 | $38.75 |
| P/E Ratio | $77.32 | ★ N/A |
| Revenue Growth | 17.62 | ★ 21.19 |
| 52 Week Low | $49.26 | $11.14 |
| 52 Week High | $70.98 | $27.61 |
Technical Indicators
Market Signals| Indicator | BMRN | QXO |
|---|---|---|
| Relative Strength Index (RSI) | 31.36 | 39.52 |
| Support Level | $58.03 | $11.14 |
| Resistance Level | $60.36 | $12.84 |
| Average True Range (ATR) | 1.43 | 0.52 |
| MACD | -0.71 | 0.07 |
| Stochastic Oscillator | 9.83 | 33.82 |
Price Performance
Historical ComparisonAbout BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
About QXO QXO Inc.
QXO Inc is a publicly traded distributor of building products in North America. The company is executing its plan to become the tech-enabled leader in the around $800 billion building products distribution industry and generate outsized value for its shareholders. The group expects to achieve its target of nearly $50 billion in annual revenues within the next decade through accretive acquisitions and organic growth.